HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.
PMID: 22592516
2012
The Pediatric infectious disease journal
Abstract: Among adolescents with chronic HBV infection, 88% have received lamivudine; however, 69% have HBV DNA >10 copies/mL and 75% had the rtM204V/I mutation.
Abstract: HBV DNA quantitation and rtM204V/I mutation analysis (lamivudine resistance-associated mutatio
Method: HBV Mutation Analysis assessed the presence of rtM204V/I by pinpointing the change in the YMDD motif; HBV nucleotides were translated into amino acid sequences using the translation tool provided by the ExPASy Proteomics Server (available at: http://www.expasy.ch/tools/dna.html) at the Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University.
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.
Discussion: In the longitudinal study of the patient sequentially treated with LMV, ADV, and ETV monotherapies, the blind SD-based algorithm ranked the 7 NA resistance-related aa substitutions previously detected by routine analysis (rtL180M, rtM204V, rtS202G, rtV207I, rtA181T, rtV173L and rtI169T) as the most variable, and 5 additional NA resistance substitutions (rtV191I,
Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.
Abstract: The primary LAM resistance mutation (rtM204V/I) occurs in the YMDD motif of HBV polymerase.
Introduction: The main site within the HBV rt protein that is associated with LAM resistance is residue 204 in the highly conserved tyrosine-methionine
Result: Interestingly, all but two individuals whose major virus population was composed of WT isolates and a small percentage of resistant variants detected by pyrosequencing had a YIDD variant as a minor subpopulation, suggesting that the rtM204I mutation may naturally occur more often and replicate more efficiently than YVDD variants in environments with little or no selection pressures.
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
Abstract: After 12-month treatment, 8.1% (3/37) of patients in group A and 5.7% (2/35) of patients in group B had VR; among patients in group A, two had rtM204V/I and rtL180M and one had rtN236T, whereas the two patients in group B had rtM204I+rtL180M.
"Evaluation of a ""home-made"" method to determine viral genotype and characterize mutations conferring drug resistance in chronic hepatitis B patients."
Abstract: HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.
Result: Late HBV breakthrough occurred in 3 patients and was associated with the emergence of 3TC-resistance mutations: rtV173L+L180M+M204I, rtL180M+M204V and rtL180M+M204I.
Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.
Abstract: RESULTS: Among 467 consecutive eligible patients (262 chronic hepatitis B patients, 105 cirrhotic patients and 100 hepatocellular carcinoma patients), the nucleos(t)ide analogues-related mutations (rtI169T, rtV173L, rtL180M, rtA181T, rtS202C, rtM204I/V, rtN236T) were found.
Result: Among patients with lamivudine related resistan
Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Abstract: Among these patients, six harbored the rtM204I mutation, two harbored the rtL180M + rtM204I mutations, one harbored the rtM204I + rtM204V mutations, one harbored the rtL80I + rtM204I mutations, and one harbored the rtV173L + rtL180M + rtM204V mutations.
Abstract: This patient was
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
1Abstract: Interestingly, none of HBV-A patients had mutation rtM204I under ADV add-on treatment but all of them had the ""V"" AA substitution."
Abstract: In HBV-D treated patients the dominant resistance mutation was rtL80V (31.4%) and rtM204I (60%) in LAM+ADV group while LAM-treated patients showed a preference of rtM204V (51.9%).
HBV mutation literature information.
PMID: 
2012
The Pediatric infectious disease journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT